Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that positive safety and efficacy Phase …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, reports its financial results for the first …
On May 4, Bioline RX Ltd (NASDAQ:BLRX) announced the expansion stage of the Phase 2 clinical trial for BL-8040, a drug for acute myeloid …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced successful completion of the dose …
As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with …
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today successful top-line results from …
BioLineRx (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that it has closed its previously announced underwritten …
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced positive pre-clinical results for BL-9020, …
BioLineRx Ltd. (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced the filing of regulatory submissions required to …
(BUSINESS WIRE)–Jan. 14, 2015– BioLineRx Ltd.
